Zhong Liu

Dr. Zhong Liu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 June 2020 in JAMA
Verified
Journal Article
Open access
PDF file
LLLing Li
Ling Li
WZWei Zhang
Wei Zhang
YHYu Hu
Yu Hu
XTXunliang Tong
Xunliang Tong
SZShangen Zheng
Shangen Zheng
ZLZhong Liu
Zhong Liu
Since December 2019, coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has spread rapidly around the world, with high rates of transmission and substantial mortality. COVID-19 symptoms can range from mild, self-limited respiratory disease to severe progressive pneumonia, multiple organ failure, and even death.1,2 To date, there is no effective treatment or vaccine to contain the disease.

6 July 2020 in Transfusion
Verified
Journal Article
Closed access
PDF file
LLLing Li
Ling Li
XTXunliang Tong
Xunliang Tong
HCHanwei Chen
Hanwei Chen
RHRui He
Rui He
QLQilu Lv
Qilu Lv
ZLZhong Liu
Zhong Liu

7 January 2021 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
LLLing Li
Ling Li
CTChianru Tan
Chianru Tan
JZJia Zeng
Jia Zeng
CLChen Luo
Chen Luo
SHShi Hu
Shi Hu
ZLZhong Liu
Zhong Liu
Background: COVID-19 has caused a global pandemic and the death toll is increasing. However, there is no definitive information regarding the type of clinical specimens that is the best for SARS-CoV-2 detection, the antibody levels in patients with different duration of disease, and the relationship between antibody level and viral load. Methods: Nasopharyngeal swabs, anal swabs, saliva, blood, and urine specimens were collected from patients with a course of disease ranging from 7 to 69 days. Viral load in different specimen types was measured using droplet digital PCR (ddPCR). Meanwhile, anti-nucleocapsid protein (anti-N) IgM and IgG antibodies and anti-spike protein receptor-binding domain (anti-S-RBD) IgG antibody in all serum samples were tested using ELISA. Results: The positive detection rate in nasopharyngeal swab was the highest (54.05%), followed by anal swab (24.32%), and the positive detection rate in saliva, blood, and urine was 16.22%, 10.81%, and 5.41%, respectively. However, some patients with negative nasopharyngeal swabs had other specimens tested positive. There was no significant correlation between antibody level and days after symptoms onset or viral load. Conclusions: Other specimens could be positive in patients with negative nasopharyngeal swabs, suggesting that for patients in the recovery period, specimens other than nasopharyngeal swabs should also be tested to avoid false negative results, and anal swabs are recommended. The antibody level had no correlation with days after symptoms onset or the viral load of nasopharyngeal swabs, suggesting that the antibody level may also be affected by other factors.

25 June 2015 in Transfusion
Verified
Journal Article
Closed access
PDF file
YYYonghua Yin
Yonghua Yin
CLChang‐Qing Li
Chang‐Qing Li
ZLZhong Liu
Zhong Liu

1 April 2017 in Transfusion Medicine Reviews
Verified
Journal Article
Closed access
LLLing Li
Ling Li
KLKa Yi Li
Ka Yi Li
KYKe Yan
Ke Yan
GOGuojin Ou
Guojin Ou
WLWenhui Li
Wenhui Li
YWYanyun Wu
Yanyun Wu

1 October 2020 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
YKYujie Kong
Yujie Kong
CCChen Cai
Chen Cai
LLLi Ling
Li Ling
LZLi Zeng
Li Zeng
MWMeihong Wu
Meihong Wu
ZLZhong Liu
Zhong Liu